Ivosidenib

Overview

Ivosidenib (AG-120) is an orally active inhibitor of isocitrate dehydrogenase 1 mutant (mIDH1) enzyme , it exhibits profound d-2-hydroxyglutatrate (2-HG) lowering in vivo. Ivosidenib (AG-120) has the potential for AML therapy due to its acceptable safety profile and clinical activity.

Application

Products | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > SARS-CoV-2 Infection | Products > Disease Areas > Cancer | Products > Disease Areas > Infection | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Metabolic or Endocrine Disease | Products > Disease Areas > Coronavirus Infection | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Metabolic Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Isocitrate Dehydrogenase (IDH)

Product Information

• Catalog No.: HY-18767
• CAS No.: 1448347-49-6
• Molecular Formula: C28H22ClF3N6O3
• Molecular Weight: 582.96
• Purity: 99.89%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 5 mg/mL (8.58 mM); Clear solution
• Availability: In-stock

Source

Original product source